NYSE:PBH

Prestige Consumer Healthcare Stock Forecast, Price & News

$42.50

+3.23 (+8.23 %)

(As of 01/26/2021 12:00 AM ET)

Add

Compare

Today's Range

$41.77

Now: $42.50▼

$44.63

50-Day Range

$34.60

MA: $36.51▼

$38.10

52-Week Range

$27.40

Now: $42.50▼

$46.12

Volume2.56 million shs

Average Volume475,084 shs

Market Capitalization$2.13 billion

P/E Ratio13.20

Dividend YieldN/A

Beta0.76

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids/lozenges, Clear Eyes for eye allergies/redness relief, Compound W wart removals, Debrox ear wax removals, DenTek for PEG oral care, and Dramamine for motion sickness relief. It also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, Fess nasal saline spray, and Hydralyte for oral rehydration products. The company sells through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

MarketRank^™

Overall MarketRank^™

1.58 out of 5 stars

Consumer Discretionary Sector

110th out of 570 stocks

Pharmaceutical Preparations Industry

168th out of 773 stocks

3.2 Analyst's Opinion

Consensus Rating
Prestige Consumer Healthcare has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 3 buy ratings, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $80.17, Prestige Consumer Healthcare has a forecasted upside of 88.6% from its current price of $42.50.
Amount of Analyst Coverage
Prestige Consumer Healthcare has only been the subject of 4 research reports in the past 90 days.

2.8 Community Rank

Outperform Votes
Prestige Consumer Healthcare has received 461 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Prestige Consumer Healthcare has received 363 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Prestige Consumer Healthcare has received 55.95% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Prestige Consumer Healthcare and other stocks. Vote “Outperform” if you believe PBH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PBH will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Prestige Consumer Healthcare does not currently pay a dividend.
Dividend Growth
Prestige Consumer Healthcare does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Prestige Consumer Healthcare insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.20% of the stock of Prestige Consumer Healthcare is held by insiders.

1.9 Earnings and Valuation

Earnings Growth
Earnings for Prestige Consumer Healthcare are expected to grow by 3.14% in the coming year, from $3.18 to $3.28 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Prestige Consumer Healthcare is 13.20, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.12.
Price to Earnings Ratio vs. Sector
The P/E ratio of Prestige Consumer Healthcare is 13.20, which means that it is trading at a less expensive P/E ratio than the Consumer Discretionary sector average P/E ratio of about 46.39.
Price to Earnings Growth Ratio
Prestige Consumer Healthcare has a PEG Ratio of 2.96. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Prestige Consumer Healthcare has a P/B Ratio of 1.82. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Pharmaceutical preparations

Sub-IndustryPersonal Products

SectorConsumer Discretionary

Current SymbolNYSE:PBH

Previous Symbol

CUSIP74112D10

CIK1295947

Webwww.prestigebrands.com

Phone914-524-6800

Employees520

Year FoundedN/A

Debt

Debt-to-Equity Ratio1.22

Current Ratio1.98

Quick Ratio1.14

Price-To-Earnings

Trailing P/E Ratio13.20

Forward P/E Ratio13.36

P/E Growth2.96

Sales & Book Value

Annual Sales$963.01 million

Price / Sales2.21

Cash Flow$4.13 per share

Price / Cash Flow10.29

Book Value$23.30 per share

Price / Book1.82

Profitability

EPS (Most Recent Fiscal Year)$2.96

Net Income$142.28 million

Net Margins17.03%

Return on Equity13.76%

Return on Assets4.80%

Miscellaneous

Outstanding Shares50,104,000

Market Cap$2.13 billion

Next Earnings Date2/4/2021 (Confirmed)

OptionableOptionable

$42.50

+3.23 (+8.23 %)

(As of 01/26/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive PBH News and Ratings via Email

Sign-up to receive the latest news and ratings for PBH and its competitors with MarketBeat's FREE daily newsletter.

Prestige Consumer Healthcare (NYSE:PBH) Frequently Asked Questions

How has Prestige Consumer Healthcare's stock price been impacted by Coronavirus (COVID-19)?

Prestige Consumer Healthcare's stock was trading at $35.91 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PBH stock has increased by 18.4% and is now trading at $42.50.
View which stocks have been most impacted by COVID-19.

Is Prestige Consumer Healthcare a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prestige Consumer Healthcare in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Prestige Consumer Healthcare stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PBH, but not buy additional shares or sell existing shares.
View analyst ratings for Prestige Consumer Healthcare or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Prestige Consumer Healthcare?

Wall Street analysts have given Prestige Consumer Healthcare a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Prestige Consumer Healthcare wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Ronald M. Lombardi's approval rating as Prestige Consumer Healthcare's CEO?

8 employees have rated Prestige Consumer Healthcare CEO Ronald M. Lombardi on Glassdoor.com. Ronald M. Lombardi has an approval rating of 61% among Prestige Consumer Healthcare's employees. This puts Ronald M. Lombardi in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Prestige Consumer Healthcare's next earnings date?

Prestige Consumer Healthcare is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for Prestige Consumer Healthcare.

How can I listen to Prestige Consumer Healthcare's earnings call?

Prestige Consumer Healthcare will be holding an earnings conference call on Thursday, February 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Prestige Consumer Healthcare's earnings last quarter?

Prestige Consumer Healthcare Inc. (NYSE:PBH) posted its quarterly earnings data on Thursday, November, 5th. The company reported $0.78 EPS for the quarter, topping the Zacks' consensus estimate of $0.72 by $0.06. The firm had revenue of $237.42 million for the quarter, compared to the consensus estimate of $227.43 million. Prestige Consumer Healthcare had a net margin of 17.03% and a trailing twelve-month return on equity of 13.76%. The firm's quarterly revenue was down .3% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.68 earnings per share.
View Prestige Consumer Healthcare's earnings history.

What guidance has Prestige Consumer Healthcare issued on next quarter's earnings?

Prestige Consumer Healthcare issued an update on its FY22 earnings guidance on Thursday, November, 5th. The company provided earnings per share (EPS) guidance of approx $3.18 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.25.

What price target have analysts set for PBH?

7 equities research analysts have issued twelve-month target prices for Prestige Consumer Healthcare's stock. Their forecasts range from $39.00 to $125.00. On average, they expect Prestige Consumer Healthcare's stock price to reach $80.17 in the next year. This suggests a possible upside of 88.6% from the stock's current price.
View analysts' price targets for Prestige Consumer Healthcare or view Wall Street analyst' top-rated stocks.

Who are some of Prestige Consumer Healthcare's key competitors?

Some companies that are related to Prestige Consumer Healthcare include The Estée Lauder Companies (EL), Herbalife Nutrition (HLF), Nu Skin Enterprises (NUS), Medifast (MED), Inter Parfums (IPAR), USANA Health Sciences (USNA), Revlon (REV), Veru (VERU) and Nature's Sunshine Products (NATR).
View all of PBH's competitors.

What other stocks do shareholders of Prestige Consumer Healthcare own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Prestige Consumer Healthcare investors own include Pfizer (PFE), AbbVie (ABBV), Gilead Sciences (GILD), AT&T (T), Intel (INTC), ONEOK (OKE), Wells Fargo & Company (WFC), International Business Machines (IBM), Micron Technology (MU) and Teva Pharmaceutical Industries (TEVA).

Who are Prestige Consumer Healthcare's key executives?

Prestige Consumer Healthcare's management team includes the following people:

Mr. Ronald M. Lombardi, Chairman, Pres & CEO (Age 57, Pay $1.98M)
Ms. Christine Sacco, Chief Financial Officer (Age 45, Pay $930.5k)
Mr. Jeffrey Zerillo, Sr. VP of Operations (Age 60, Pay $480.41k)
Mr. William C. P'Pool, Sr. VP, Gen. Counsel & Corp. Sec. (Age 56, Pay $735.71k)
Mr. Adel Mekhail, Exec. VP of Marketing & Sales (Age 60, Pay $679.38k)
Mr. Philip David Terpolilli, Director of Investor Relations
Dean Siegal, Director of Communications
Ms. Mary Beth Fritz, Sr. VP of Quality & Regulatory Affairs

What is Prestige Consumer Healthcare's stock symbol?

Prestige Consumer Healthcare trades on the New York Stock Exchange (NYSE) under the ticker symbol "PBH."

Who are Prestige Consumer Healthcare's major shareholders?

Prestige Consumer Healthcare's stock is owned by many different institutional and retail investors. Top institutional investors include Wedge Capital Management L L P NC (0.50%), Peregrine Capital Management LLC (0.47%), Dalton Greiner Hartman Maher & Co. (0.24%), Nisa Investment Advisors LLC (0.05%), Skyline Asset Management LP (0.03%) and Diversified Trust Co (0.03%). Company insiders that own Prestige Consumer Healthcare stock include Paton Brett and Ronald M Lombardi.
View institutional ownership trends for Prestige Consumer Healthcare.

Which major investors are selling Prestige Consumer Healthcare stock?

PBH stock was sold by a variety of institutional investors in the last quarter, including Skyline Asset Management LP, Dalton Greiner Hartman Maher & Co., Wedge Capital Management L L P NC, Pacer Advisors Inc., Diversified Trust Co, OLD National Bancorp IN, Janney Montgomery Scott LLC, and State of Alaska Department of Revenue.
View insider buying and selling activity for Prestige Consumer Healthcare or view top insider-selling stocks.

Which major investors are buying Prestige Consumer Healthcare stock?

PBH stock was bought by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, XTX Markets LLC, Nisa Investment Advisors LLC, and Exchange Traded Concepts LLC.
View insider buying and selling activity for Prestige Consumer Healthcare or or view top insider-buying stocks.

How do I buy shares of Prestige Consumer Healthcare?

Shares of PBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Prestige Consumer Healthcare's stock price today?

One share of PBH stock can currently be purchased for approximately $42.50.

How big of a company is Prestige Consumer Healthcare?

Prestige Consumer Healthcare has a market capitalization of $2.13 billion and generates $963.01 million in revenue each year. The company earns $142.28 million in net income (profit) each year or $2.96 on an earnings per share basis. Prestige Consumer Healthcare employs 520 workers across the globe.

What is Prestige Consumer Healthcare's official website?

The official website for Prestige Consumer Healthcare is www.prestigebrands.com.

How can I contact Prestige Consumer Healthcare?

Prestige Consumer Healthcare's mailing address is 660 WHITE PLAINS ROAD SUITE 250, TARRYTOWN NY, 10591. The company can be reached via phone at 914-524-6800 or via email at [email protected]

This page was last updated on 1/26/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here